Trial reportBMC anesthesiology2026
Preemptive noradrenaline infusion: a game-changer against post-induction hypotension in surgical sepsis: a randomized double blind trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07022730 (The Novel Use of Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension in Patients With Surgical Sepsis, a Double Blind Randomized Controlled Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Novel Use of Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension in Patients With Surgical Sepsis, a Double Blind Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-induction hypotension is a frequent and clinically significant complication in patients with sepsis undergoing source control surgery, often leading to adverse outcomes such as acute kidney injury. Despite its prevalence, targeted strategies to prevent post-induction hypotension in this population remain underexplored. We aimed to evaluate the efficacy of prophylactic noradrenaline infusion (0.2 µg/kg/min) in reducing the incidence of post-induction hypotension in patients with surgical sepsis.
methodsIn this randomized controlled trial, 80 adult patients with surgical sepsis were allocated to receive either noradrenaline infusion or saline placebo before anesthesia induction. Baseline demographics, laboratory values, and intraoperative parameters were also recorded. The primary outcome was the incidence of postinduction hypotension, defined as a > 20% reduction in mean arterial pressure within 10 min of induction. The secondary outcomes included the time to the first hypotensive episode, ephedrine requirements, incidence of acute kidney injury, and other postoperative complications.
resultsThe baseline characteristics were comparable between the groups. The noradrenaline group demonstrated a significantly lower incidence of post-induction hypotension (10% vs. 45%, p < 0.001). Moreover, the incidence of acute kidney injury was markedly lower in the noradrenaline-treated cohort (5%) than in the saline-control group (23%). In contrast, no statistically significant differences were observed between the groups with respect to other clinical outcomes, including myocardial infarction, renal replacement therapy, stroke, and delirium.
conclusionProphylactic noradrenaline infusion before anesthesia induction significantly improves hemodynamic stability and reduces the risk of acute kidney injury in patients with sepsis undergoing source control surgery. These findings support the use of this technique as a safe and effective strategy for preventing post-induction hypotension in high-risk surgical populations.
trial registrationThe clinical study was registered on ClinicalTrials.gov by the principal investigator, M. Helmy, under the identifier NCT07022730 on June 7, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.